(Q45162737)

10 December 2017

Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol (English)

1 reference

10 December 2017

0 references

U Breyer-Pfaff

1

1 reference

PubMed ID

15563768

10 December 2017

K Nill

series ordinal

2

1 reference

10 December 2017

1 December 2004

1 reference

Journal of Pharmacy and Pharmacology

10 December 2017

1 reference

10 December 2017

56

1 reference

10 December 2017

12

1 reference

10 December 2017

1601-1606

1 reference

Characterization of the novel 5-HT3 antagonists MDL 73147EF (dolasetron mesilate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells

10 December 2017

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Mammalian carbonyl reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Short-chain dehydrogenases/reductases (SDR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Pharmacokinetics of haloperidol: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Short-chain dehydrogenases/reductases (SDR): the 2002 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Ondansetron clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Immunohistochemical localization of carbonyl reductase in human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Characterization of a novel variant (S145C/L311V) of 3 ??-hydroxysteroid/dihydrodiol dehydrogenase in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

Serum time course of naltrexone and 6β-naltrexol levels during long term treatment in drug addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357045020

21 January 2018

Identifiers

DOI

10.1211/0022357045020

1 reference

10 December 2017

1 reference

PubMed ID

15563768